IDEAYA Biosciences, Inc.

IDYANASDAQHealthcare● Active

$30.72

+$2.43(+8.59%)

Market Cap$2.7B

P/E Ratio—

52W High$39.28

52W Low$20.455

Avg Volume1.1M

Open$28.84

Beta-0.05

Free Cash Flow Financials Revenue

IDEAYA Biosciences, Inc. (IDYA) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

IDYA · free cash flow · updated Jun 8, 2026

Core FCF metrics

IDYA · FCF · TTM · margin & CAGR

Free cash flow was −$73.5M for FY2025 (fiscal year ending 2025-12-31), up 70.8% year-over-year The FCF margin was -33.6%.

FY2025 Free Cash Flow−$73.5M▲ +70.8% YoY

Trailing 12M (TTM)−$87.9Mtrailing 4 quarters sum

FCF Margin-33.6%−$73.5M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

IDYA · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$71.1M(2M)−$73.5M▲ +70.8%-33.6%

FY2024−$247.6M(4M)−$251.4M▼ 113.8%—

FY2023−$115.2M(2M)−$117.6M▼ 29.8%-502.9%

FY2022−$87.2M(3M)−$90.6M▼ 55.1%-177.9%

FY2021−$55.8M(3M)−$58.4M▼ 206.3%-209.1%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

IDYA · P/FCF · FCF yield · FCF per share

IDEAYA Biosciences, Inc. (IDYA) reported negative free cash flow of −$0.07B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

IDYA · cash flow statement · operating / investing / financing

For FY2025, IDEAYA Biosciences, Inc. generated −$71.1M in operating cash flow and spent 2M in capital expenditures, yielding −$73.5M in free cash flow.

Operating Activities

−$71.1M

Cash from core business operations

2025-12-31

Investing Activities

+$70.0M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$29.8M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$71.1M) − |CapEx| (2M) = FCF (−$73.5M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

IDYA vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

IDEAYA Biosciences, Inc.YOU

IDYA

−$73.5M+70.8%-33.6%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

IDEAYA Biosciences, Inc. (IDYA) reported free cash flow of −$73.5M for FY2025 (fiscal year ending 2025-12-31), up 70.8% year-over-year. The FCF margin was -33.6%.

Based on available data, IDEAYA Biosciences, Inc. has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $55.0M in FY2020.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

IDYA free cash flow · 8 questions

IDEAYA Biosciences, Inc. free cash flow was −$73.5M for FY2025, up 70.8% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$87.9M.

IDYA free cash flowIDYA FCFIDYA FCF 2025IDYA free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · IDEAYA Biosciences, Inc. · IDEAYA Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026